|
End-of-day quote
Borsa Italiana
24/09/2026
|
5-day change | 1st Jan Change | ||
| 72.12 EUR | -1.48% |
|
-4.02% | -13.15% |
| 24/09 | US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes | RE |
| 23/09 | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
| Market Cap | 8.64TCr 9.82TCr 8.14TCr 7.43TCr 14TCr 9,42700Cr 14TCr 98TCr 38TCr 4,79800Cr 37TCr 36TCr 15,61200Cr | P/E 2026 * |
11.5x | P/E 2027 * | 10x |
|---|---|---|---|---|---|
| Enterprise Value | 9.78TCr 11TCr 9.22TCr 8.42TCr 16TCr 10,67800Cr 16TCr 1,10700Cr 43TCr 5,43400Cr 42TCr 41TCr 17,68400Cr | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | 1.87x |
| Free-Float |
88.34% | Yield 2026 * |
5.9% | Yield 2027 * | 6.24% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| SAN | Real-time | |
CBOE
| SAN | Real-time | |
|
London S.E.
| 0O59 | Delayed | |
|
Xetra
| SNW | Delayed | |
|
Tradegate
| SNW | Real-time | |
|
Börse Stuttgart
| SNW | Delayed | |
|
Deutsche Boerse AG
| SNW | Delayed | |
|
Boerse Muenchen
| SNW | Real-time | |
|
Borsa Italiana
| 1SAN | End-of-day quote | |
|
Mexican S.E.
| SAN1 N | End-of-day quote | |
|
Wiener Boerse
| SANO | End-of-day quote | |
|
OTC Markets
| SNYN.F | Delayed | |
|
Bulgaria S.E.
| SNW | End-of-day quote | |
|
Swiss Exchange
| SAN | Delayed | |
|
CBOE
| 0O59 | Real-time |
Last Transcript: Sanofi
| 1 day | -1.48% | ||
| 1 week | -4.02% | ||
| Current month | -6.02% | ||
| 1 month | -7.90% | ||
| 3 months | -1.78% | ||
| 6 months | -7.41% | ||
| Current year | -13.15% |
| 1 week | 72.12 |  | 74.58 |
| 1 month | 72.12 | | 80 |
| Current year | 71.27 | | 84.9 |
| 1 year | 71.27 | | 90.78 |
| 3 years | 71.27 | | 111 |
| 5 years | 71.27 | | 111 |
| 10 years | 63.15 | | 111 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.48% | -4.02% | - | - | 9.98TCr | |
| +2.68% | +2.56% | +59.32% | +114.68% | 1,02600Cr | |
| +0.56% | +0.17% | +53.19% | +68.65% | 65TCr | |
| +0.02% | +0.42% | +20.51% | +73.58% | 47TCr | |
| +0.06% | +0.61% | +39.82% | +45.71% | 35TCr | |
| +1.16% | +2.53% | +21.60% | +29.39% | 27TCr | |
| -0.24% | -0.23% | +10.62% | +12.26% | 26TCr | |
| -0.01% | +6.91% | +45.42% | +51.68% | 22TCr | |
| -1.11% | -0.80% | +31.69% | +99.56% | 19TCr | |
| +0.30% | -9.43% | -31.91% | -60.56% | 17TCr | |
| Average | -0.08% | +0.52% | +27.81% | +48.33% | 39.99TCr | |
| Weighted average by Cap. | +0.08% | +1.06% | +38.36% | +67.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.76TCr 5.42TCr 4.49TCr 4.1TCr 7.66TCr 5,20000Cr 7.72TCr 54TCr 21TCr 2,64600Cr 20TCr 20TCr 8,61200Cr | 5.06TCr 5.76TCr 4.77TCr 4.36TCr 8.15TCr 5,52700Cr 8.21TCr 57TCr 22TCr 2,81300Cr 22TCr 21TCr 9,15300Cr |
| Net income | 747.87Cr 850.24Cr 705.01Cr 643.22Cr 1.2TCr 82TCr 1.21TCr 8.46TCr 3.28TCr 42TCr 3.19TCr 3.12TCr 1,35200Cr | 888.61Cr 1.01TCr 837.68Cr 764.26Cr 1.43TCr 97TCr 1.44TCr 10TCr 3.9TCr 49TCr 3.79TCr 3.71TCr 1,60600Cr |
| Net Debt | 1.15TCr 1.3TCr 1.08TCr 985.93Cr 1.84TCr 1,25100Cr 1.86TCr 13TCr 5.03TCr 64TCr 4.89TCr 4.79TCr 2,07200Cr | 833.58Cr 947.69Cr 785.81Cr 716.94Cr 1.34TCr 91TCr 1.35TCr 9.43TCr 3.65TCr 46TCr 3.56TCr 3.48TCr 1,50700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | €72.12 | -1.48% | 1,864 |
| 23/26/23 | €73.20 | -1.28% | 3,911 |
| 22/26/22 | €74.15 | -0.56% | 717 |
| 21/26/21 | €74.57 | +0.66% | 680 |
| 18/26/18 | €74.08 | -1.41% | 1,016 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- 1SAN Stock
Select your edition
All financial news and data tailored to specific country editions
